Redeye comments on Isofol’s study update from its ongoing phase Ib/II trial with arfolitixorin.
2025 har varit ett turbulent år för Elon med flera överraskande rubriker kring upptäckta fel vid red...
* Minor negative estimate revisions due to lower headcount * Continued negative net recruitment tren...
Redeye comments on Gentoo Media’s Q4-results which were in line with the preliminary results announc...
Redeye comments on Cheffelo’s Q4 2025 report, which was strong overall, with net sales of SEK323.
Redeye comments on Cantargia's fourth quarter report 2025.
After a volatile prior period, 2025 marked a recovery for mid-cap biotech.
* Market remains challenging; soft near-term outlook * We lower '26e-'27e adj.
* Weak ACV, but good margins * We lower our sales assumptions, but raise '26e-'27e EBIT margins * 1.
Med god historik och en fantastisk kursutveckling har Björn Borg expanderat och blivit ett globalt m...
Beyond Frames redovisade totala intäkter om 39,8 MSEK (50,9), varav nettoomsättningen uppgick till 2...
Teneo AI:s CEO Per Ottosson provides an update on the latest developments concerning the company.
* Q4: Back to growth and positive EBIT; sales +12% vs.
Nivika Fastigheter avslutade helåret 2025 starkt. Hyresintäkterna steg 11% till 753 mkr, driftöversk...
Redeye is encouraged to see Absolent returning to organic growth of 10% in the fourth quarter as BA ...
* Q4 numbers largely in-line with expectations * Large move-out in Q1 weighs on outlook * 2026e P/CE...
We expect continued good growth in Q4 and fairly flat margin development q/q.
Redeye updates its estimates and valuation following Navigo releasing its Q4 2025 report.
Redeye provides an update following CLS’s Q4 2025 report.
